These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 10969810)

  • 1. Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2,2'-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid.
    Siim BG; Laux WT; Rutland MD; Palmer BN; Wilson WR
    Cancer Res; 2000 Aug; 60(16):4582-8. PubMed ID: 10969810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Siim BG; Lee AE; Shalal-Zwain S; Pruijn FB; McKeage MJ; Wilson WR
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):43-52. PubMed ID: 12497205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid.
    Wilson WR; Li AE; Cowan DS; Siim BG
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):905-8. PubMed ID: 9845119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid.
    Cliffe S; Taylor ML; Rutland M; Baguley BC; Hill RP; Wilson WR
    Int J Radiat Oncol Biol Phys; 1994 May; 29(2):373-7. PubMed ID: 8195036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
    Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT
    Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid.
    Pruijn FB; van Daalen M; Holford NH; Wilson WR
    Cancer Chemother Pharmacol; 1997; 39(6):541-6. PubMed ID: 9118467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
    Seshadri M; Spernyak JA; Mazurchuk R; Camacho SH; Oseroff AR; Cheney RT; Bellnier DA
    Clin Cancer Res; 2005 Jun; 11(11):4241-50. PubMed ID: 15930363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.
    Murata R; Overgaard J; Horsman MR
    Int J Radiat Biol; 2001 Feb; 77(2):195-204. PubMed ID: 11236926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
    Lash CJ; Li AE; Rutland M; Baguley BC; Zwi LJ; Wilson WR
    Br J Cancer; 1998 Aug; 78(4):439-45. PubMed ID: 9716024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours.
    Chen G; Horsman MR; Pedersen M; Pang Q; Stødkilde-Jørgensen H
    Acta Oncol; 2008; 47(6):1071-6. PubMed ID: 18770061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia.
    Ballinger JR; Kee JW; Rauth AM
    J Nucl Med; 1996 Jun; 37(6):1023-31. PubMed ID: 8683295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Cao Z; Baguley BC; Ching LM
    Cancer Res; 2001 Feb; 61(4):1517-21. PubMed ID: 11245459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
    Joseph WR; Cao Z; Mountjoy KG; Marshall ES; Baguley BC; Ching LM
    Cancer Res; 1999 Feb; 59(3):633-8. PubMed ID: 9973211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid.
    Murata R; Siemann DW; Overgaard J; Horsman MR
    Radiat Res; 2001 Nov; 156(5 Pt 1):503-9. PubMed ID: 11604063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.
    Zhao L; Kestell P; Ching LM; Baguley BC
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):20-6. PubMed ID: 11855749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of the novel hypoxic marker 99mTc-HL91 (Prognox) in murine and xenograft systems in vivo.
    Honess DJ; Hill SA; Collingridge DR; Edwards B; Brauers G; Powell NA; Chaplin DJ
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):731-5. PubMed ID: 9845086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid.
    Browne WL; Wilson WR; Baguley BC; Ching LM
    Anticancer Res; 1998; 18(6A):4409-13. PubMed ID: 9891501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Woon ST; Zwain S; Schooltink MA; Newth AL; Baguley BC; Ching LM
    Eur J Cancer; 2003 May; 39(8):1176-83. PubMed ID: 12736120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DMXAA: an antivascular agent with multiple host responses.
    Baguley BC; Ching LM
    Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1503-11. PubMed ID: 12459378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies of 99mTc-BnAO (HL-91): a non-nitroaromatic compound for hypoxic cell detection.
    Zhang X; Melo T; Ballinger JR; Rauth AM
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):737-40. PubMed ID: 9845087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.